AstraZeneca fell 9%. Bristol Myers rose 6%. Same merger report, opposite verdicts.

On 2 August, the Financial Times reported that AstraZeneca and Bristol Myers Squibb had discussed a merger that would combine two companies worth close to $400 billion: AstraZeneca at roughly $264 billion, Bristol Myers at roughly $133 billion. Reuters confirmed the talks the next day. Neither company confirmed anything itself; both declined to comment.

By the close of trading that week, AstraZeneca shares had fallen as much as 7% before finishing down about 9%, the stock's biggest one-day drop since 2020. Bristol Myers gained roughly 6% in premarket trading the same morning. No deal exists yet, and the market has already split into two opposite verdicts on it.

What "in talks" actually is

Worth being precise about what happened here, because it's less than the headline implies. A report of talks, sourced to people familiar with the matter, is not a signed agreement, a board vote, or even a formal proposal. Plenty of reported mega-merger conversations dissolve before either side puts out a press release. The honest read of this story right now is: two companies had a conversation someone leaked, and the market is pricing a possibility, not an outcome.

Why the stocks moved in opposite directions

This pattern is common enough in M&A speculation to be worth naming: the presumed target rallies, the presumed absorber falls. It's the market pricing who bears the risk. A buyer in a large combination typically takes on integration risk and potential overpayment, plus dilution to its own shareholders if the deal is done partly in stock. A takeout target's holders, by contrast, are pricing in the chance of a premium.

JM Finn's Lucy Coutts put it plainly: "BMS shareholders would be the winners of any combination with AZN and so this news will undoubtedly be received coolly by AZN shareholders." That is the divergence in one sentence, from someone with no stake in being right about whether the deal happens.

Not every reaction was that clean. Union Investment's Markus Manns called the combination one that "does not make strategic or financial sense" and would disrupt operations. That is skepticism about the deal itself, not just who wins it. Reported talks generating a genuine split among people paid to have a view is itself informative: this isn't a market unanimously pricing in a done deal.

What each side actually needs right now

Stock moves aside, both companies arrive at this rumor carrying real pressure, and it's worth naming, because it's the difference between "this deal makes sense on paper" and "this deal solves a problem management is under pressure to solve."

AstraZeneca is coming off a clean miss. On 9 July, its cardiovascular drug Wainua (eplontersen), partnered with Ionis, failed to beat placebo on its primary endpoint in a Phase 3 trial for transthyretin-mediated amyloid cardiomyopathy. US shares fell about 8% and London-listed shares about 9% that morning. AstraZeneca has also set a public target of $80 billion in sales by 2030, a number that gets harder to hit organically after a pipeline setback of that size.

Bristol Myers is working against a calendar. The company faces loss-of-exclusivity headwinds on Eliquis and Opdivo, drugs that together represent roughly half its sales, with generic and biosimilar competition arriving toward the end of the decade. A larger partner doesn't remove that cliff. It can change how survivable the years around it are.

Neither fact makes the deal likely. Both explain why two boards might be talking at all.

What could stop it

Shore Capital's Sean Conroy flagged the more concrete obstacle: overlap between the two companies' cancer immunotherapy portfolios could draw antitrust scrutiny in a combination this size. AstraZeneca's oncology strength sits mostly in solid tumors; Bristol Myers's in blood cancers and cell therapy — complementary on the surface, but a deal of this scale invites regulators to look past the surface. That review, if a deal ever gets that far, would run on its own multi-month clock, independent of anything the stock prices this week.

What to watch

• Whether either company issues a formal statement. Under a "no comment" posture, this remains speculation regardless of how the stocks trade.
• Whether the story is denied. A denial that turns out to be technically true today and wrong in three months would not be the first in this industry, but a clean denial is still a different data point than silence.
• The ESC Congress data on Wainua in August, which AstraZeneca has said will include a fuller readout of the subgroup that appeared to benefit, which bears on how much pressure the company is actually under.

The portable lesson: when a merger is still just reported talks, the stock reaction is not a verdict on the deal — it's a verdict on who the market thinks would pay for it. That split is real information. Whether the deal itself is real is a separate question, and right now nobody outside those two boardrooms has an answer to it.

This is analysis, not investment advice. It describes what has been disclosed and what has not, and does not recommend any position in any security.